In Silico Drug Discovery Market to Grow with a CAGR of 7.99% through 2030
Growth of precision and
personalized medicine and expansion of cloud computing and high-performance
infrastructure are factors driving the Global In Silico Drug Discovery Market in the forecast period 2026-2030.
According to the
TechSci Research report, “In Silico Drug Discovery Market - Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global In Silico Drug Discovery Market stood at USD 3.22 billion in 2024
and is anticipated to grow with a CAGR of 7.99% through 2030. Traditional drug discovery is expensive,
slow, and has a high failure rate. In-silico methods reduce the number of
physical compounds needed for synthesis and testing by simulating molecular
interactions digitally. This lowers early-stage screening costs and helps
companies identify promising leads more quickly, improving R&D
productivity.
AI
and machine learning have transformed drug discovery. Tools such as generative
AI, predictive modeling, and molecular docking algorithms can simulate complex
biological interactions and predict drug efficacy with higher accuracy. These
capabilities increase confidence that computational “hits” will translate into
real drug candidates, encouraging greater investment.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global
In Silico Drug Discovery Market ”
Earlier,
computational drug discovery required large, expensive in-house infrastructure.
Today, cloud platforms offer scalable, cost-effective computing power, making
advanced software tools accessible to startups, mid-sized biotech firms, and
academic institutions. This democratization accelerates adoption and drives
competition in the market.
The Global In
Silico Drug Discovery Market is segmented into Component, Workflow, Software
Type, Technology, Therapeutic Area, End User, regional distribution, and
company.
Based
on the end user, the Contract Research Organizations segment is dominating the
global In Silico Drug Discovery Market in 2024, due to their growing reliance
on outsourcing drug discovery and development processes. CROs offer specialized
computational platforms and expertise that allow pharmaceutical and biotech
companies to accelerate preclinical studies, optimize candidate selection, and
reduce overall research costs. By leveraging in silico technologies, CROs can
simulate molecular interactions, predict drug efficacy, and identify potential
safety concerns earlier in the development pipeline. Additionally, the rising
number of partnerships between CROs and biotech firms to adopt advanced
computational tools further strengthens their market position, making them the
preferred end users of in silico drug discovery solutions.
The
Asia Pacific is the fastest-growing region in the Global In Silico Drug
Discovery Market in 2024, is driven by the increasing reliance of
pharmaceutical and biotechnology companies on outsourcing to optimize research
efficiency and reduce costs. CROs leverage advanced computational tools,
AI-driven modeling, and predictive analytics to accelerate drug discovery while
minimizing experimental failures. Their expertise allows for faster target
identification, virtual screening, and lead optimization, making them a
preferred partner for innovation-focused companies. Additionally, rising
R&D costs, regulatory pressures, and the demand for precision medicine
further reinforce CROs’ central role in in-silico drug discovery.
Major companies
operating in the Global In Silico Drug Discovery Market are:
- Aragen Life
Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
- Curia
Global, Inc. (Albany Molecular Research Inc.)
- Charles
River Laboratories International, Inc.
- Chemical
Computing Group ULC. (CCG)
- Collaborative
Drug Discovery Inc. (CDD)
- e-therapeutics
plc.
- Dassault
Systèmes SE
- Insilico
Medicine, Inc.
- Numerate,
Inc.
- Schrödinger,
Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The rise of precision medicine requires
analyzing massive biological datasets — such as genomic, proteomic, and
clinical data — to design therapies for specific patient subgroups. In-silico
platforms excel at integrating such data and predicting how a drug will perform
in targeted populations, making them essential tools for personalized drug
discovery, “said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“In Silico Drug Discovery Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2020-2030F Segmented By
Component (Software, Software-as-a-Service, Consultancy-as-a-Service), By
Workflow (Discovery, Pre-Clinical Tests, Clinical Trials), By Software Type
(Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling
Software), By Technology (Artificial Intelligence, Graphics Processing Unit,
Others), By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious
Diseases, Metabolic Disorders, Oncology Disorders, Others), By End User
(Biotechnology & Pharmaceutical Companies, Contract Research Organizations,
Academic & Research Organizations, Others), By Region and Competition ”,
has evaluated the future growth potential of Global In Silico Drug Discovery Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the Global In Silico Drug Discovery Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com